CAR-Tscm Cells As an Effective Immune Treatment to Multiple Myeloma Patients

Objective：

Since T memory stem cell (TSCM) is a kind of cell with strong self-renewal ability, long-term persistence, proliferation ability and anti-tumor activity, and is an ideal candidate cell for cancer immunotherapy. We aimed to explore the amount of TSCM cells in multiplt myeloma（MM） and the established a method to expansion TSCM in vitro, and to further explore the effect of CAR-T cells prepared by TSCM on MM cells.

Methods：

TSCM cells (CD45RA+CCR7+CD62L+CD95+) were detected with Flow cytometry, further induced TSCM cells expansion in vitro by using IL-2+MEKi+Il-15 combination, TSCM cell-based CAR-T cells were constructed in vitro, further the therapeutic effect of CAR-Tscm cells in MM-loaded NSG mouse model were explored.

Results：

The proportion of TSCM cells is reduced in patients with MM, but their function is stronger than that of CTL cells, and the use of IL-2+ Meki+Il-15 in vitro can induce the expansion of TSCM cells and promote their antitumor capacity; Further, Targeting BCMA CAR-Tscm cells as an effective immune treatment to multiple myeloma patients. CAR-T cells were constructed using TSCM cells in vitro, and in vitro experiments confirmed that they had similar killing effects to conventional CAR-T cells on MM cells in an NSG mouse model of MM tumor burden; CAR-Tscm cells were demonstrated to have similar effects to conventional CAR-T therapy, and demonstrated stronger antitumor effects than conventional CAR-T in contralateral tumorigenic models.

Conclusion：

CAR-Tscm cells are a potentially effective treatment for multiple myeloma.

No relevant conflicts of interest to declare.